Eric Hau
YOU?
Author Swipe
View article: Metabolic reprogramming in diffuse intrinsic pontine gliomas (DIPG): dual inhibition of mitochondrial oxidative phosphorylation and lactate metabolism to enhance anti-tumor and radiosensitizing effects in DIPG cells
Metabolic reprogramming in diffuse intrinsic pontine gliomas (DIPG): dual inhibition of mitochondrial oxidative phosphorylation and lactate metabolism to enhance anti-tumor and radiosensitizing effects in DIPG cells Open
Background Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), are universally fatal pediatric brain tumors with no effective treatments. DIPG tumors actively utilize mitochondrial oxidative phosphorylation…
View article: The glioblastoma biomechanical landscape: A systematic review of magnetic resonance elastography (MRE) of brain tumors and healthy brain
The glioblastoma biomechanical landscape: A systematic review of magnetic resonance elastography (MRE) of brain tumors and healthy brain Open
Diagnosis of a glioblastoma (GBM) brain tumor is associated with very poor prognosis. Currently, few preclinical models used to identify new therapies address the soft brain tissue environment and GBM mechanoresponses, which are implicated…
View article: Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review
Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review Open
Lung cancer remains the leading cause of cancer‐related mortality in Australia, with diagnoses projected to rise further following the introduction of the National Lung Cancer Screening Program in July 2025. Comprehensive molecular profili…
View article: Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial – protocol for a phase II study
Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial – protocol for a phase II study Open
Background Trans Tasman Radiation Oncology Group 20.01 CHEST-RT (Chemotherapy and Immunotherapy in Extensive Stage Small cell with Thoracic Radiotherapy) is a single-arm, open-label, prospective, multicentre phase II trial study that aims …
View article: Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non–Small Cell Lung Cancer: A Systematic Review
Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non–Small Cell Lung Cancer: A Systematic Review Open
Shortening treatment time with moderately hypofractionated radiotherapy benefits patients by reducing inconvenience and costs, but its use in the definitive treatment of unresectable Stage 3 non–small cell lung cancer is controversial due …
View article: Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With <scp>NSCLC</scp> and Brain Metastases: A Systematic Review and Network Meta‐Analysis
Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With <span>NSCLC</span> and Brain Metastases: A Systematic Review and Network Meta‐Analysis Open
Background Multiple studies have demonstrated the intracranial efficacy of immune checkpoint inhibitors (ICI) +/− chemotherapy. The efficacy of chemoimmunotherapy compared to ICI alone in patients with metastatic NSCLC and brain metastases…
View article: Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage
Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage Open
Double-strand breaks (DSBs) can initiate mitotic catastrophe, a complex oncosuppressive phenomenon characterized by cell death during or after cell division. Here we unveil how cell cycle-regulated DSB repair guides disparate cell death ou…
View article: Inhibition of mitochondrial bioenergetics and hypoxia to radiosensitize diffuse intrinsic pontine glioma
Inhibition of mitochondrial bioenergetics and hypoxia to radiosensitize diffuse intrinsic pontine glioma Open
Background Diffuse intrinsic pontine gliomas (DIPGs) and other H3K27M-mutated diffuse midline gliomas (DMGs) are brain tumors that primarily affect children. Radiotherapy is the standard of care but only provides only temporary symptomatic…
View article: DDDR-11. INHIBITING OXIDATIVE PHOSPHORYLATION AND HYPOXIA WITH ATOVAQUONE – A STRATEGY TO RADIOSENSITIZE DIFFUSE MIDLINE GLIOMA
DDDR-11. INHIBITING OXIDATIVE PHOSPHORYLATION AND HYPOXIA WITH ATOVAQUONE – A STRATEGY TO RADIOSENSITIZE DIFFUSE MIDLINE GLIOMA Open
Diffuse midline glioma (DMG) is a uniformly fatal paediatric brainstem tumour with median survival of less than 1 year. Radiotherapy has been the only effective treatment for decades, but most DMGs recur within several months due to radior…
View article: Cardiac Substructure Dose and Survival in Stereotactic Radiotherapy for Lung Cancer: Results of the Multi-Centre SSBROC Trial
Cardiac Substructure Dose and Survival in Stereotactic Radiotherapy for Lung Cancer: Results of the Multi-Centre SSBROC Trial Open
Patients treated with lung SABR may receive high doses to cardiac substructures. Dichotomising the patients according to median mean heart dose showed a clear difference in survival. On multivariable analyses gender and dose to ascending a…
View article: Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy
Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy Open
Patients with advanced NSCLC have heterogenous responses to immune checkpoint inhibitors (ICIs) with or without chemotherapy. In NSCLC, the impact of the distribution of metastatic sites and the response to systemic therapy combinations re…
View article: Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study Open
In patients with oligoprogressive metastatic NSCLC after treatment with first-line ICIs, radiotherapy significantly improves OS and PFS2 outcomes. Patients with baseline brain metastases are more likely to experience oligoprogression. Furt…
View article: Homologous recombination promotes mitotic death to suppress the innate immune response
Homologous recombination promotes mitotic death to suppress the innate immune response Open
Double strand breaks (DSBs) can initiate mitotic catastrophe, a complex oncosuppressive phenomenon characterized by cell death during or after cell division. Through single-cell analysis of extended live imaging, we unveiled how cell cycle…
View article: Radiation therapy for ventricular arrhythmias
Radiation therapy for ventricular arrhythmias Open
Ventricular arrhythmias (VA) can be life‐threatening arrhythmias that result in significant morbidity and mortality. Catheter ablation (CA) is an invasive treatment modality that can be effective in the treatment of VA where medications fa…
View article: First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study Open
Introduction Brain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation, is either chemoimmunotherapy or anti-PD-1 monotherapy. Tradit…
View article: DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA
DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA Open
Diffuse Midline Glioma (DMG) is a uniformly fatal paediatric brainstem tumour with median survival of less than 1 year. Radiotherapy has been the only effective treatment for decades, but most DMGs recur within several months due to radior…
View article: DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM Open
Diffuse Midline Gliomas (DMG) is the leading cause of brain tumor-related death in children. Currently, radiation is the only treatment that offers transient benefit but almost all DMG relapse due to radioresistance. Compared to normal bra…
View article: Data from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Data from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism Open
Because radiotherapy significantly increases median survival in patients with glioblastoma, the modulation of radiation resistance is of significant interest. High glycolytic states of tumor cells are known to correlate strongly with radio…
View article: Table S1 from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Table S1 from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism Open
Table S1. The surviving fractions of GBM cell lines after treatment with DCA as a single agent.
View article: Data from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Data from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism Open
Because radiotherapy significantly increases median survival in patients with glioblastoma, the modulation of radiation resistance is of significant interest. High glycolytic states of tumor cells are known to correlate strongly with radio…
View article: Table S1 from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Table S1 from Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism Open
Table S1. The surviving fractions of GBM cell lines after treatment with DCA as a single agent.
View article: Use of durvalumab in stage <scp>III</scp> n<scp>on‐small</scp>‐cell lung cancer based on eligibility for the <scp>PACIFIC</scp> study
Use of durvalumab in stage <span>III</span> n<span>on‐small</span>‐cell lung cancer based on eligibility for the <span>PACIFIC</span> study Open
Background Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for …
View article: Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment Open
Summary Immune checkpoint inhibition with PD‐1/PD‐L1 blockade is a promising area in the field of anti‐cancer therapy. Although clinical data have revealed success of PD‐1/PD‐L1 blockade as monotherapy or in combination with CTLA‐4 or chem…